Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bryan C. Cannon is active.

Publication


Featured researches published by Bryan C. Cannon.


Journal of the American College of Cardiology | 2008

Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients.

Charles I. Berul; George F. Van Hare; Naomi J. Kertesz; Anne M. Dubin; Frank Cecchin; Kathryn K. Collins; Bryan C. Cannon; Mark E. Alexander; John K. Triedman; Edward P. Walsh; Richard A. Friedman

OBJECTIVES We sought to determine the implications of implantable cardioverter-defibrillator (ICD) placement in children and patients with congenital heart disease (CHD). BACKGROUND There is increasing frequency of ICD use in pediatric and CHD patients. Until recently, prospective registry enrollment of ICD patients was not available, and children and CHD patients account for only a small percentage of ICD recipients. Therefore, we retrospectively obtained collaborative data from 4 pediatric centers, aiming to identify implant characteristics, shock frequency, and complications in this unique population. METHODS Databases from 4 centers were collated in a blinded fashion. Demographic information, implant electrical parameters, appropriate and inappropriate shock data, and complications were recorded for all implants from 1992 to 2004. RESULTS A total of 443 patients were included, with a median age of 16 years (range 0 to 54 years) and median weight of 61 kg (range 2 to 130 kg), with 69% having structural heart disease. The most common diagnoses were tetralogy of Fallot (19%) and hypertrophic cardiomyopathy (14%). Implant indication was primary prevention in 52%. Shock data were available on 409 patients, of whom 105 (26%) received appropriate shocks (mean 4 shocks/patient, range 1 to 29 shocks/patient). Inappropriate shocks occurred in 87 of 409 patients (21%), with a mean of 6 per patient (range 1 to 60), mainly attributable to lead failure (14%), sinus or atrial tachycardias (9%), and/or oversensing (4%). CONCLUSIONS Children and CHD ICD recipients have significant appropriate and inappropriate shock frequencies. Optimizing programming, medical management, and compliance may diminish inappropriate shocks. Despite concerns regarding generator recalls, lead failure remains the major cause of inappropriate shocks, complications, and system malfunction in children. Prospective assessment of ICD usage in this population may identify additional important factors in pediatric and CHD patients.


British Journal of Sports Medicine | 2013

Electrocardiographic interpretation in athletes: the ‘Seattle Criteria’

Jonathan A. Drezner; Michael J. Ackerman; Jeffrey M. Anderson; Euan A. Ashley; Chad A. Asplund; Aaron L. Baggish; Mats Börjesson; Bryan C. Cannon; Domenico Corrado; John P. DiFiori; Peter S. Fischbach; Victor F. Froelicher; Kimberly G. Harmon; Hein Heidbuchel; Joseph Marek; David S. Owens; Stephen Paul; Antonio Pelliccia; Jordan M. Prutkin; Jack C. Salerno; Christian Schmied; Sanjay Sharma; Ricardo Stein; Victoria L. Vetter; Mathew G Wilson

Sudden cardiac death (SCD) is the leading cause of death in athletes during sport. Whether obtained for screening or diagnostic purposes, an ECG increases the ability to detect underlying cardiovascular conditions that may increase the risk for SCD. In most countries, there is a shortage of physician expertise in the interpretation of an athletes ECG. A critical need exists for physician education in modern ECG interpretation that distinguishes normal physiological adaptations in athletes from abnormal findings suggestive of pathology. On 13–14 February 2012, an international group of experts in sports cardiology and sports medicine convened in Seattle, Washington, to define contemporary standards for ECG interpretation in athletes. The objective of the meeting was to develop a comprehensive training resource to help physicians distinguish normal ECG alterations in athletes from abnormal ECG findings that require additional evaluation for conditions associated with SCD.


Heart Rhythm | 2012

PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic Pattern

Mitchell I. Cohen; John K. Triedman; Bryan C. Cannon; Andrew M. Davis; Fabrizio Drago; Jan Janousek; George J. Klein; Ian H. Law; Fred Morady; Thomas Paul; James C. Perry; Shubhayan Sanatani; Ronn E. Tanel

C PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic Pattern Developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS)


Journal of the American College of Cardiology | 2015

40-Year Follow-Up After the Fontan Operation: Long-Term Outcomes of 1,052 Patients.

Kavitha N. Pundi; Jonathan N. Johnson; Joseph A. Dearani; Krishna Pundi; Zhuo Li; Cynthia A. Hinck; Sonja H. Dahl; Bryan C. Cannon; Patrick W. O’Leary; David J. Driscoll; Frank Cetta

BACKGROUND There are limited long-term, single-cohort, follow-up studies available about patients after the Fontan operation. OBJECTIVES This study sought to determine the long-term outcome of all patients who had a Fontan operation at the Mayo Clinic. METHODS Records of all patients who had a modified Fontan operation between 1973 and 2012 were reviewed. A follow-up questionnaire was mailed to all patients alive at the time of the study. RESULTS Overall, 10-, 20-, and 30-year survival for 1,052 patients was 74%, 61%, and 43%, respectively. Factors associated with decreased overall or late survival in multivariate analysis included pre-operative diuretic use, longer cardiopulmonary bypass time, operation prior to 1991, atrioventricular valve (AVV) replacement at the time of Fontan operation, elevated post-bypass Fontan (>20 mm Hg) or left atrial (>13 mm Hg) pressures, prolonged chest tube drainage (>21 days), post-operative ventricular arrhythmias, renal insufficiency, and development of protein-losing enteropathy (PLE). Pre-operative and intraoperative sinus rhythm were associated with improved survival. Long-term survival was similar for patients regardless of ventricular morphology. The most common reoperations were pacemaker insertion/revision in 212 patients (20%), Fontan revision/conversion in 117 patients (11%), and AVV repair/replacement in 66 patients (5%). Clinically significant late atrial or ventricular arrhythmias occurred in 468 patients (44%). Ninety-five patients (9%) developed PLE, and 5-, 10-, and 20-year survival after diagnosis of PLE was 50%, 35%, and 19%, respectively. CONCLUSIONS As the surgical techniques for the Fontan operation have changed over the last 40 years, survival has improved. However, development of PLE and arrhythmias and the need for reoperation during long-term follow-up pose significant management challenges.


British Journal of Sports Medicine | 2013

Normal electrocardiographic findings: recognising physiological adaptations in athletes

Jonathan A. Drezner; Peter S. Fischbach; Victor F. Froelicher; Joseph Marek; Antonio Pelliccia; Jordan M. Prutkin; Christian Schmied; Sanjay Sharma; Mathew G Wilson; Michael J. Ackerman; Jeffrey M. Anderson; Euan A. Ashley; Chad A. Asplund; Aaron L. Baggish; Mats Börjesson; Bryan C. Cannon; Domenico Corrado; John P. DiFiori; Kimberly G. Harmon; Hein Heidbuchel; David S. Owens; Stephen Paul; Jack C. Salerno; Ricardo Stein; Victoria L. Vetter

Electrocardiographic changes in athletes are common and usually reflect benign structural and electrical remodelling of the heart as a physiological adaptation to regular and sustained physical training (athletes heart). The ability to identify an abnormality on the 12-lead ECG, suggestive of underlying cardiac disease associated with sudden cardiac death (SCD), is based on a sound working knowledge of the normal ECG characteristics within the athletic population. This document will assist physicians in identifying normal ECG patterns commonly found in athletes. The ECG findings presented as normal in athletes were established by an international consensus panel of experts in sports cardiology and sports medicine.


Pacing and Clinical Electrophysiology | 2006

Innovative techniques for placement of implantable cardioverter- defibrillator leads in patients with limited venous access to the heart

Bryan C. Cannon; Richard A. Friedman; Arnold L. Fenrich; Charles D. Fraser; E. Dean McKenzie; Naomi J. Kertesz

Background: Because of venous occlusion, intracardiac shunting, previous surgery, or small size placement of implantable cardioverter‐defibrillator (ICD) leads may not be possible using traditional methods. The purpose of this study was to evaluate and describe innovative methods of placing ICD leads.


British Journal of Sports Medicine | 2013

Abnormal electrocardiographic findings in athletes: recognising changes suggestive of cardiomyopathy

Jonathan A. Drezner; Euan A. Ashley; Aaron L. Baggish; Mats Börjesson; Domenico Corrado; David S. Owens; Akash R. Patel; Antonio Pelliccia; Victoria L. Vetter; Michael J. Ackerman; Jeffrey M. Anderson; Chad A. Asplund; Bryan C. Cannon; John P. DiFiori; Peter S. Fischbach; Victor F. Froelicher; Kimberly G. Harmon; Hein Heidbuchel; Joseph Marek; Stephen Paul; Jordan M. Prutkin; Jack C. Salerno; Christian Schmied; Sanjay Sharma; Ricardo Stein; Mathew G Wilson

Cardiomyopathies are a heterogeneous group of heart muscle diseases and collectively are the leading cause of sudden cardiac death (SCD) in young athletes. The 12-lead ECG is utilised as both a screening and diagnostic tool for detecting conditions associated with SCD. Fundamental to the appropriate evaluation of athletes undergoing ECG is an understanding of the ECG findings that may indicate the presence of an underlying pathological cardiac disorder. This article describes ECG findings present in cardiomyopathies afflicting young athletes and outlines appropriate steps for further evaluation of these ECG abnormalities. The ECG findings defined as abnormal in athletes were established by an international consensus panel of experts in sports cardiology and sports medicine.


British Journal of Sports Medicine | 2013

Abnormal electrocardiographic findings in athletes: recognising changes suggestive of primary electrical disease

Jonathan A. Drezner; Michael J. Ackerman; Bryan C. Cannon; Domenico Corrado; Hein Heidbuchel; Jordan M. Prutkin; Jack C. Salerno; Jeffrey M. Anderson; Euan A. Ashley; Chad A. Asplund; Aaron L. Baggish; Mats Börjesson; John P. DiFiori; Peter S. Fischbach; Victor F. Froelicher; Kimberly Harmon; Joseph Marek; David S. Owens; Stephen Paul; Antonio Pelliccia; Christian Schmied; Sanjay Sharma; Ricardo Stein; Victoria L. Vetter; Mathew G Wilson

Cardiac channelopathies are potentially lethal inherited arrhythmia syndromes and an important cause of sudden cardiac death (SCD) in young athletes. Other cardiac rhythm and conduction disturbances also may indicate the presence of an underlying cardiac disorder. The 12-lead ECG is utilised as both a screening and a diagnostic tool for detecting conditions associated with SCD. Fundamental to the appropriate evaluation of athletes undergoing ECG is an understanding of the ECG findings that may indicate the presence of a pathological cardiac disease. This article describes ECG findings present in primary electrical diseases afflicting young athletes and outlines appropriate steps for further evaluation of these ECG abnormalities. The ECG findings defined as abnormal in athletes were established by an international consensus panel of experts in sports cardiology and sports medicine.


Journal of the American College of Cardiology | 2009

Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children.

Jamie A. Decker; Joseph W. Rossano; E. O'Brian Smith; Bryan C. Cannon; Sarah K. Clunie; Corey M. Gates; John L. Jefferies; Jeffrey J. Kim; Jack F. Price; William J. Dreyer; Jeffrey A. Towbin; Susan W. Denfield

OBJECTIVES This study was designed to review outcomes of pediatric isolated hypertrophic cardiomyopathy (HCM) managed uniformly at a single institution and assess whether reported adult risk factors for sudden death are predictive in pediatric HCM. BACKGROUND Cardiac death in HCM occurs suddenly (SCD) or may be nonsudden (non-SCD). Little data exists on non-SCD in children. Risk factors for SCD in adult HCM are characterized and consensus management strategies detailed. Their application to children is uncertain and treatment strategies vary. METHODS A retrospective cohort study of children with HCM was performed. Primary end points were cardiac death and transplantation. Frequency and outcomes of known adult risk factors were assessed. Outcomes analysis was performed using Kaplan-Meier curves and Cox regression analysis. RESULTS Ninety-six patients were included. The average age at diagnosis was 10.6 +/- 5.4 years, and mean follow-up was 6.4 +/- 5.2 years. Primary end points occurred in 11 patients over the 20-year follow-up (11%), 4 underwent cardiac transplant and 7 died (3 suddenly). Extreme left ventricular hypertrophy (z-score: >6) and an abnormal blood pressure response to exercise were predictive of non-SCD (p < 0.02 and p < 0.03, respectively). Kaplan-Meier survival analysis predicts an 82% survival over a 20-year period. CONCLUSIONS In children with isolated HCM managed primarily with exercise restriction and medication, cardiac death occurred infrequently. Non-SCD or transplant was at least as common as SCD. Extreme left ventricular hypertrophy and blunted blood pressure response to exercise were associated with an increased risk of non-SCD.


Circulation | 2013

Multi-Institutional Study of Implantable Defibrillator Lead Performance in Children and Young Adults Results of the Pediatric Lead Extractability and Survival Evaluation (PLEASE) Study

Joseph Atallah; Christopher C. Erickson; Frank Cecchin; Anne M. Dubin; Ian H. Law; Mitchell I. Cohen; Martin J. LaPage; Bryan C. Cannon; Terrence U.H. Chun; Vicki Freedenberg; Marcin Gierdalski; Charles I. Berul

Background— Implantable cardioverter-defibrillator (ICD) therapy in children and congenital heart disease patients is hampered by poor long-term lead survival. Lead extraction is technically difficult and carries substantial morbidity. We sought to determine the outcomes of ICD leads in pediatric and congenital heart disease patients. Methods and Results— The Pediatric Lead Extractability and Survival Evaluation (PLEASE) is a 24-center international registry. Pediatric and congenital heart disease patients with ICD lead implantations from 2005 to 2010 were eligible. Study subjects comprised 878 ICD patients (44% congenital heart disease). Mean±SD age at implantation was 18.6±9.8 years. Of the 965 total leads, 54% were thin (⩽7F), of which 57% were Fidelis, and 23% were coated with expanded polytetrafluoroethylene. There were 139 ICD lead failures (14%) in 132 patients (15%) at a mean lead age of 2.0±1.4 years, causing shocks in 53 patients (40%). Independent predictors of lead failure included younger implantation age and Fidelis leads. Actuarial analysis showed an incremental risk of lead failure with younger age at implantation: <8 years compared with >18 years (P=0.015). The actuarial yearly failure rate was 2.3% for non-Fidelis and 9.1% for Fidelis leads. Extraction was performed on 143 leads (80% thin, 7% expanded polytetrafluoroethylene coated), with lead age as the only independent predictor for advanced extraction techniques. There were 6 major extraction complications (4%) but no procedural mortality. Conclusions— This study demonstrates that ICD leads in children and congenital heart disease patients have an age-related suboptimal performance, further compounded by a high failure rate of Fidelis leads. Advanced extraction techniques were common and correlated with older lead age. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00335036.Background— Implantable cardioverter-defibrillator (ICD) therapy in children and congenital heart disease patients is hampered by poor long-term lead survival. Lead extraction is technically difficult and carries substantial morbidity. We sought to determine the outcomes of ICD leads in pediatric and congenital heart disease patients. Methods and Results— The Pediatric Lead Extractability and Survival Evaluation (PLEASE) is a 24-center international registry. Pediatric and congenital heart disease patients with ICD lead implantations from 2005 to 2010 were eligible. Study subjects comprised 878 ICD patients (44% congenital heart disease). Mean±SD age at implantation was 18.6±9.8 years. Of the 965 total leads, 54% were thin (≤7F), of which 57% were Fidelis, and 23% were coated with expanded polytetrafluoroethylene. There were 139 ICD lead failures (14%) in 132 patients (15%) at a mean lead age of 2.0±1.4 years, causing shocks in 53 patients (40%). Independent predictors of lead failure included younger implantation age and Fidelis leads. Actuarial analysis showed an incremental risk of lead failure with younger age at implantation: 18 years ( P =0.015). The actuarial yearly failure rate was 2.3% for non-Fidelis and 9.1% for Fidelis leads. Extraction was performed on 143 leads (80% thin, 7% expanded polytetrafluoroethylene coated), with lead age as the only independent predictor for advanced extraction techniques. There were 6 major extraction complications (4%) but no procedural mortality. Conclusions— This study demonstrates that ICD leads in children and congenital heart disease patients have an age-related suboptimal performance, further compounded by a high failure rate of Fidelis leads. Advanced extraction techniques were common and correlated with older lead age. Clinical Trial Registration— URL: . Unique identifier: [NCT00335036][1]. # Clinical Perspective {#article-title-15} [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00335036&atom=%2Fcirculationaha%2F127%2F24%2F2393.atom

Collaboration


Dive into the Bryan C. Cannon's collaboration.

Top Co-Authors

Avatar

Naomi J. Kertesz

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Arnold L. Fenrich

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Jeffrey J. Kim

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge